They give me very good support on my research and are together with me all the time. With the help from them, I made good progress with my research, which provides further understanding of B cell lymphomas.
I was awarded CRI fellowship to conduct my research at the University of Chicago. This helped us to identify pathways critical to leukemias and lymphomas.
CRI's generous and continued support of our research in cancer immunology and cancer immunotherapy helped us to establish a sustainable clinical research and teaching/training program in the field. New students and young researchers were introduced to the field as MD/PhD students and young faculty. CRI's CVC helped to establish a Clinical Trials Center at the University of Zurich. Ultra-lean management and great communication skills with an outstanding scientific faculty advising characterize CRI's success as a non-profit organization focused on Cancer Immunology and Cancer Immunotherapy.
I was awarded a CRI postdoc fellowship a few years ago, which turns me from a scientific worker to a scientist. The critical difference between these two is that the later endowed with a great passion and motivation for research which grew in me during this postdoctoral training phases. Without the support from CRI, this transformation will not likely happen. Thank CRI for training young people in the cancer research field, and I believe our research will eventually provide great benefits for cancer patients.
During my postdoctoral studies at the section of Immunobiology at Yale Medical School I have been a CRI fellow studying the transcriptional regulation of cytokine genes driving the differentiation processes of T helper cells. During that period, and having peace of mind because CRI was funding my research, we were able to advance our knowledge about gene regulation and show that the three dimensional structure of the genome affects the expression profile of a locus. More importantly others have shown that proximity of gene loci in the 3D nucleus increase the probability for a translocation event usually found in leukemia and tumors.
The funding I have received during my postdoctoral studies was of fundamental importance and helped me get an Assistant Professorship. And again my good angel CRI was there to support my research with an Investigator award. This gave a kickstart to my career and my first steps as an independent investigator. I am really proud being part of this team of people who are dedicated and hard working with the ultimate goal of conquering cancer.
I was the recipient of a CRI postdoctoral fellowship award that funded my research in the function of the innate immune system during aging at MIT. Because of the generous support of CRI, I was able to make important discoveries that I anticipate will help to form the foundation of further study in age-dependent dynamics of signaling pathways that regulate the immune response later in life. Throughout my years as a CRI fellow, I have found the staff at CRI to be professional, supportive, and truly dedicated to the cause of advancing scientific knowledge toward the goal of eliminating cancer. My heartfelt thanks goes to CRI, and I would strongly recommend CRI as a benefactor of those seeking to support biomedical research.
The Cancer Research Institute by wisely selecting and generously supporting investigators and projects on cancer research has immensely contributed to advance our understanding of malignancies, thus paving the way for novel therapies. With the support of the CRI we have developed new MHC-peptide based reagents that allow improved detection and isolation of antigen-specific CD8+ and CD8+ T lymphocytes. We endeavour after final optimization to make these reagents generally available, thus contributing to better monitor and understand cancer specific T cell immunity.
Twenty five years ago I received a posdoctoral fellowship from the CRI. This allowed me to get an unvaluable training in the field of cancer immunology that was the start of my scientific career. CRI did not mind the fact that I was a young physician just arrived in the US, and generously funded my research. CRI is the perfect example of a phylantropic organization in the frontier of new knowledge and humankind. I am now a top administrator of one of the largests European Universities and I remain grateful to CRI for their support.
As a former recipient of Cancer Research Institute postdoc fellowship, I am very grateful to CRI for the generous support to allow me to carry out frontier research work in chemical biology at Harvard University. It was an eye opening experience that not only broadened my understanding at the interface of chemistry and biology, but also gave me an inspiration to choose my own research topic related to cancer and immunology. In my independent academic work, I have benefited tremendously from that postdoctoral experience and I am glad I have made the right decision to develop new anticancer drugs.
In 2008, the Cancer Research Institute was the only agency that was
willing to fund a risky project whose objective it is to understand
why the immune system fails in the elderly. Since then, this study has
yielded exciting results on how aging of stem cells influences immune
function and we are currently preparing two manuscripts on our work.
We have recently procured a grant by the National Institute on Aging,
totaling $658,000, to follow up on these results. Obviously, we would
not have been able to undertake this project without the visionary
support of the Cancer Research Institute.